<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="464">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634007</url>
  </required_header>
  <id_info>
    <org_study_id>LX1001-01</org_study_id>
    <nct_id>NCT03634007</nct_id>
  </id_info>
  <brief_title>Gene Therapy for APOE4 Homozygote of Alzheimer's Disease</brief_title>
  <official_title>A 52-Week, Multicenter, Phase 1 Open-label Study to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexeo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Drug Discovery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lexeo Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is an open label, dose-ranging study designed to evaluate gene therapy to&#xD;
      treat patients who are APOE4 homozygotes with clinical diagnosis varying from mild cognitive&#xD;
      impairment due to Alzheimer's, mild dementia due to Alzheimer's disease, and moderate&#xD;
      dementia due to Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will have evidence of amyloid plaque by nuclear Positron emission tomography&#xD;
      (PET scan) and cerebrospinal fluid (CSF) biomarkers consistent with Alzheimer's disease. The&#xD;
      study will assess the safety and toxicity of intrathecal administration of AAVrh.10hAPOE2,&#xD;
      serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the complementary&#xD;
      deoxyribonucleic acid (cDNA) coding for human apolipoprotein E2 (APOE2), directly to the&#xD;
      central nervous system (CNS)/ CSF of APOE4 homozygotes with Alzheimer's disease. The study&#xD;
      will establish a maximum tolerable dose and generate preliminary evidence regarding whether&#xD;
      direct administration of AAVrh.10hAPOE2 to the CNS of those Alzheimer's patients will lead to&#xD;
      conversion of the APOE protein isoforms in the CSF of APOE4 homozygotes from APOE4 to&#xD;
      APOE2-APOE4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2019</start_date>
  <completion_date type="Anticipated">September 23, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with treatment-emergent adverse events and serious adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events categorized and graded</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of participants with treatment-emergent adverse events and serious adverse events at each dosage</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events categorized and graded per study drug dose</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Early Onset Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Cohort I: 5.0 x 10^10 gc/mL CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.0 x 10^10 gc/mL CSF of LX1001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II: 1.6 x 10^11 gc/mL CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.6 x 10^11 gc/mL CSF of LX1001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort III: 5.0 x 10^11 gc/mL CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.0 x 10^11 gc/mL CSF of LX1001</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LX1001</intervention_name>
    <description>LX1001 (AAVrh.10hAPOE2) is a serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human apolipoprotein E2 (APOE2).</description>
    <arm_group_label>Cohort I: 5.0 x 10^10 gc/mL CSF</arm_group_label>
    <arm_group_label>Cohort II: 1.6 x 10^11 gc/mL CSF</arm_group_label>
    <arm_group_label>Cohort III: 5.0 x 10^11 gc/mL CSF</arm_group_label>
    <other_name>AAVrh.10hAPOE2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  APOE4 homozygotes&#xD;
&#xD;
          -  Males and females, age 50 or older&#xD;
&#xD;
          -  Willing and able to provide informed consent (or consent provided by legally&#xD;
             authorized representative)&#xD;
&#xD;
          -  Mild cognitive impairment due to Alzheimer's disease, or clinical diagnosis of mild to&#xD;
             moderate dementia due to Alzheimer's disease&#xD;
&#xD;
          -  Evidence of amyloid plaques by nuclear PET scan and cerebrospinal fluid (CSF)&#xD;
             biomarkers consistent with Alzheimer's disease&#xD;
&#xD;
          -  Serum neutralizing anti-AAVrh10 titer &lt;1:100&#xD;
&#xD;
          -  No evidence of active infection of any type, including hepatitis virus (A, B or C) or&#xD;
             human immunodeficiency virus (HIV-1 and HIV-2)&#xD;
&#xD;
          -  Fertile or infertile individuals; it will be recommended that fertile individuals&#xD;
             utilize barrier birth control measures to prevent pregnancy for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Individuals not receiving experimental medications or participating in another&#xD;
             experimental protocol for at least 4 weeks prior to entry to the study&#xD;
&#xD;
          -  Participants who agree not to post their personal data related to the study on social&#xD;
             media.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals receiving receiving systemic corticosteroids, other immunosuppressive&#xD;
             medications, Aduhelm (aducanumab), other immunosuppressive medications, or&#xD;
             anti-coagulant medications (other than aspirin)&#xD;
&#xD;
          -  Individuals who do not fit the American Journal of Neuroradiology recommendations for&#xD;
             image guided spinal procedures&#xD;
&#xD;
          -  Presence of other significant medical or neurological conditions may disqualify the&#xD;
             subject from participation in this study, particularly those which would create an&#xD;
             unacceptable risk to receiving the AAVrh.10APOE2 vector, for example, malignancy,&#xD;
             heart failure, liver or renal failure, or HIV positive.&#xD;
&#xD;
          -  Evidence of ongoing infection&#xD;
&#xD;
          -  Elevated white blood cell count, temperature &gt;38.5ÌŠ C, infiltrate on chest x-ray&#xD;
&#xD;
          -  Prior or concurrent participation in any gene and/or cell therapy&#xD;
&#xD;
          -  Any condition, disorder, or abnormal laboratory test findings at screening which, in&#xD;
             the judgment of the investigator, would interfere with the individual's ability to&#xD;
             comply with all study requirements, or would require the administration of treatment&#xD;
             during the study that could potentially affect the interpretation of the study data,&#xD;
             or would place the individual at an unacceptable risk by his/her participation in the&#xD;
             study&#xD;
&#xD;
          -  Individuals who cannot participate in MRI, PET and CSF studies&#xD;
&#xD;
          -  Individuals who cannot undergo study-related procedures without general anesthesia&#xD;
&#xD;
          -  More than 4 cerebral microhemorrhages (regardless of their anatomical location or&#xD;
             diagnostic characterization as &quot;possible&quot; or &quot;definite&quot;), a single area of superficial&#xD;
             siderosis, or evidence of a prior macrohemorrhage&#xD;
&#xD;
          -  Are pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lexeo Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Lexeo Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lexeo Clinical Trials</last_name>
    <phone>+1 212-547-9879</phone>
    <email>clinicaltrials@lexeotx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lexeo Clinical Trials</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PPD Development</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Poissant</last_name>
      <phone>689-216-3179</phone>
      <email>Sarah.Poissant@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065-4870</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Bowe</last_name>
      <phone>646-962-2672</phone>
      <email>hab40007@med.cornell.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>July 11, 2022</last_update_submitted>
  <last_update_submitted_qc>July 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

